UNCYUnicycive Therapeutics Inc
UNCY
Unicycive Therapeutics Inc3,139
Mkt Cap
$203.92MVolume
500.0052W High
$11.0052W Low
$3.71PE Ratio
-4.02UNCY Fundamentals
Price
$8.13Prev Close
$8.08Open
$8.1850D MA
$6.98Beta
0.81Avg. Volume
549,348.29EPS (Annual)
-$1.67P/B
5.95Rev/Employee
$0.00$50.60
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Recommendation of "Moderate Buy" by Analysts
Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the six analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and five...
MarketBeat·2d ago
Unicycive Therapeutics (NASDAQ:UNCY) Downgraded to Sell Rating by Wall Street Zen
Wall Street Zen cut shares of Unicycive Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat·5d ago
B. Riley Financial Begins Coverage on Unicycive Therapeutics (NASDAQ:UNCY)
B. Riley Financial assumed coverage on shares of Unicycive Therapeutics in a report on Friday. They issued a "buy" rating and a $22.00 price target on the stock...
MarketBeat·6d ago
Equities Analysts Offer Predictions for UNCY Q1 Earnings
Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Analysts at Brookline Capital Markets issued their Q1 2026 earnings per share estimates for Unicycive Therapeutics in a research note issued on Tuesday, April 7th. Brookline Capital Markets analyst K. Raja expects that the company will post...
MarketBeat·27d ago
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Rating of "Moderate Buy" by Brokerages
Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the five ratings firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and four have assi...
MarketBeat·27d ago
Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YORK, April 9, 2026 NEW YORK, April 9, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is...
PR Newswire·28d ago
Brookline Capital Markets Estimates UNCY Q2 Earnings
Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Brookline Capital Markets issued their Q2 2026 earnings per share estimates for shares of Unicycive Therapeutics in a report issued on...
MarketBeat·28d ago
Benchmark Cuts Unicycive Therapeutics (NASDAQ:UNCY) Price Target to $15.00
Benchmark lowered their target price on shares of Unicycive Therapeutics from $21.00 to $15.00 and set a "speculative buy" rating for the company in a research note on Monday...
MarketBeat·1mo ago
HC Wainwright Issues Positive Estimate for UNCY Earnings
Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Equities research analysts at HC Wainwright increased their Q1 2026 EPS estimates for Unicycive Therapeutics in a note issued to investors on Tuesday, March 31st. HC Wainwright analyst S. Ramakanth now anticipates that the company will post...
MarketBeat·1mo ago
Guggenheim Has Lowered Expectations for Unicycive Therapeutics (NASDAQ:UNCY) Stock Price
Guggenheim decreased their price target on Unicycive Therapeutics from $46.00 to $40.00 and set a "buy" rating on the stock in a research note on Thursday...
MarketBeat·1mo ago
<
1
2
...
>